WINDTREE THERAPEUTICS INC /DE/
WINT evidence brief
What we can confirm
- Market Cap:
- $10K
What it means
What to watch
Prepared research question
What matters most for WINT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WINT
Windtree Therapeutics is a biotechnology company developing early- and late-stage therapies for critical conditions, with a lead Phase 2 candidate for cardiogenic shock and a preclinical oncology program.
Key risk: Very low cash runway
Market Cap
$10K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
Windtree Therapeutics is a biotechnology company developing early- and late-stage therapies for critical conditions, with a lead Phase 2 candidate for cardiogenic shock and a preclinical oncology program.
- Lead candidate istaroxime is a Phase 2 dual-mechanism agent for acute heart failure and cardiogenic shock [sec · filed 2025-07-10].
- Preclinical pipeline includes SERCA2a activators for heart failure and an aPKCi inhibitor for solid tumors [sec · filed 2025-07-10].
- Rostafuroxin, a Phase 2 candidate for hypertension with a specific genetic profile, is licensed to Lee's Pharmaceutical for Greater China [pipeline].
- Cash & equivalents were $0.2M as of 2025-09-30, with net income of -$28.1M and negative shareholders' equity of -$11.6M [sec].
- The company intends to use equity to acquire subsidiaries and has a management team with commercialization expertise [sec · filed 2025-07-10].
What works
- Istaroxime has received Fast Track regulatory status, indicating potential for expedited development [pipeline].
- The company has a partnership with Lee's Pharmaceutical for development and commercialization in Greater China for istaroxime and rostafuroxin [pipeline].
- Management team has commercialization expertise across large pharma and small biotech, which may help optimize future commercial performance [sec · filed 2025-07-10].
What to weigh
- Cash position is very low at $0.2M as of 2025-09-30, with negative shareholders' equity of -$11.6M, indicating severe financial constraints [sec].
- The company acknowledges it may not be able to continue funding operations with existing cash and equivalents [sec · filed 2025-07-10].
- Rostafuroxin development is dependent on securing licensing or partnership arrangements, and the company does not intend to advance it alone [sec · filed 2025-07-10].
- The aPKCi inhibitor is in preclinical stage with a highly competitive landscape of over 370 competitors [pipeline].
From the filings
Quoted directly from source documents.
Lead candidate istaroxime is a Phase 2 dual-mechanism agent for acute heart failure and cardiogenic shock.
“Our lead product candidate, istaroxime, is a first-in-class, dual-mechanism agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure”
SEC filings · July 10, 2025
Catalyst timeline
- 2024-06-01 · Phase 2 start for istaroxime in cardiogenic shock — A multicenter, randomized, placebo-controlled trial evaluating safety and efficacy of istaroxime for cardiogenic shock SCAI Stage C.
Risks & what to watch (4)›
Key risks
- Very low cash runway — Cash & equivalents of $0.2M as of 2025-09-30 may not sustain operations for long [sec].
- Negative shareholders' equity — Shareholders' equity of -$11.6M as of 2025-09-30 indicates liabilities exceed assets [sec].
- Dependence on partnerships for rostafuroxin — Company will not advance rostafuroxin without a licensing or strategic partnership [sec · filed 2025-07-10].
- Preclinical aPKCi in crowded field — aPKCi inhibitor faces over 370 competitors in solid tumors [pipeline].
What to watch
- Istaroxime Phase 2 trial for cardiogenic shock, with a catalyst date of 2024-06-01 for Phase 2 start [catalyst].
- Ability to secure additional financing given low cash position [sec · filed 2025-07-10].
- Progress of preclinical SERCA2a activators and aPKCi inhibitor toward clinical development [sec · filed 2025-07-10].
- Potential licensing or partnership for rostafuroxin [sec · filed 2025-07-10].
Sources: Catalysts · Pipeline · SEC filings · Generated October 4, 2026 · How we verify sources →
Run WINDTREE THERAPEUTICS INC /DE/ through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available WINDTREE THERAPEUTICS INC /DE/ facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2025Institutional holders
6
Total value held
$9K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 14,599 | $8K |
| tower research capital llc (trc) | 2,212 | $1K |
| bank of america corp /de/ | 103 | $53 |
| sbi securities co., ltd. | 24 | $12 |
| ubs group ag | 22 | $11 |
| concourse financial group securities, inc. | 0 | $0 |
Short Interest
as of May 22, 2026- % of float
- 6.3%
- Days to cover
- 0.1
- Shares short
- 1,790,483
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WINT short interestFrequently asked questions
What is the AI investment thesis for WINDTREE THERAPEUTICS INC /DE/?
Windtree Therapeutics is a biotechnology company developing early- and late-stage therapies for critical conditions, with a lead Phase 2 candidate for cardiogenic shock and a preclinical oncology program.
Who is the CEO of WINDTREE THERAPEUTICS INC /DE/?
Mr. Jed A. Latkin is the chief executive officer of WINDTREE THERAPEUTICS INC /DE/ (WINT).
Where is WINDTREE THERAPEUTICS INC /DE/ headquartered?
WINDTREE THERAPEUTICS INC /DE/ (WINT) is headquartered in Warrington, PA, United States.
What therapeutic areas does WINDTREE THERAPEUTICS INC /DE/ focus on?
WINDTREE THERAPEUTICS INC /DE/ develops therapies across Oncology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.